含有益生菌的甲基酸盐/富可伊丹水凝,用于促进口腔的愈合
Xue Dou1, Guotai Li2, Shuang Wang3
1Department of Stomatology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266003, China; School of Stomatology, Qingdao University, Qingdao 266023, China.
International journal of biological macromolecules
|June 10, 2023
概括
这项研究开发了新的益生菌载荷的水凝贴片,含有富可伊丹,用于增强口腔的愈合. 这些生物活性贴片显示出卓越的治疗效果和治疗口腔的巨大潜力.
科学领域:
- 生物材料科学 生物材料科学
- 口腔医学是指口腔医学.
- 再生医学是一种再生医学.
背景情况:
- 益生菌为组织修复提供抗菌和免疫调节的好处.
- 富科伊丹 (FD) 是一种海洋益生菌,可以增强益生菌在治愈中的有效性.
- 目前口服益生菌和FD的输送方法对于湿口腔环境来说是不理想的.
研究的目的:
- 开发新型含益生菌的甲基酸盐/富可伊丹复合水凝,作为生物活性口腔贴片.
- 评估这些水凝的物理化学特性,生物相容性和治疗潜力,用于治疗口腔.
主要方法:
- 复合水凝的制造包括益生菌和fucoidan.
- 评估水凝特性:粘附性,胀性,机械强度,药物释放性和储存稳定性.
- 在体外评估生物相容性 (细胞/血液相容性) 和抗菌活性.
- 在体内研究,比较水凝贴片与商业贴片的疗效,以促进口腔的愈合.
主要成果:
- 开发的水凝具有出色的湿组织粘附性,适当的胀和机械性能,持续的益生菌释放,以及良好的储存耐用性.
- 在体外测试证实了水凝的优良细胞/血液兼容性和抗菌作用.
- 在体内研究表明,生物活性水凝在促进愈的过程中具有卓越的治疗能力,由增强的细胞迁移,上皮形成,原沉积和新血管化证明.
结论:
- 含有益生菌的甲基酸盐/富可伊丹复合液体是治疗口腔的有前途的先进材料.
- 这些新型生物活性贴片在促进有效的口腔伤口愈合方面,比传统治疗方法具有显著的优势.
相关概念视频
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
575
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
575
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
513
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
513
01:29Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
01:26Peptic Ulcer Disease IV: Management
115
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
115